Immunogenicity of the rF1+rV vaccine for plague with identification of potential immune correlates

Microbial Pathogenesis

Volumn 42, Issue 1, 2007, Pages 11-21

  Williamson, E D ^a   Flick Smith, H C ^a   Waters, E ^a   Miller, J ^a   Hodgson, I ^a   Le Butt, C S ^a   Hill, J ^a  

^a DEFENCE SCIENCE AND TECHNOLOGY LABORATORY   (United Kingdom)

Author keywords

Immune correlates; Immunogenicity; Macaque; Plague; rF1+rV; Vaccine

Indexed keywords

ALUMINUM HYDROXIDE; ANTIGEN; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 7.3; PLAGUE VACCINE; RECOMBINANT PROTEIN F1 PLUS RECOMBINANT PROTEIN V; V ANTIGEN;

ADSORPTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN BINDING; ARTICLE; ASSAY; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOTOXICITY; DRUG FORMULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; IN VITRO STUDY; MACROPHAGE; MOUSE; NONHUMAN; PLAGUE; PRIORITY JOURNAL; PROVOCATION TEST; QUALITATIVE ANALYSIS; SERUM; YERSINIA;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; CYTOTOXICITY TESTS, IMMUNOLOGIC; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNIZATION SCHEDULE; IMMUNIZATION, PASSIVE; IMMUNOGLOBULIN G; MACACA FASCICULARIS; MALE; MICE; MICE, INBRED BALB C; PLAGUE; PLAGUE VACCINE; PORE FORMING CYTOTOXIC PROTEINS; RECOMBINANT PROTEINS; VACCINES, SUBUNIT; VACCINES, SYNTHETIC; YERSINIA PESTIS;

ANIMALIA; MACACA; MURINAE; YERSINIA;

EID: 33845581662     PISSN: 08824010     EISSN: 10961208     Source Type: Journal    
DOI: 10.1016/j.micpath.2006.09.003     Document Type: Article

References (41)

1. Anon. Prevention of plague: recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep 45 (1996) 1-15
2. Anon. Human plague in 1998 and 1999. WHO Wkly Epidemiol Rec 75 (2000) 337-344
3. Perry R.D., and Fetherston J.D. Yersinia pestis-etiologic agent of plague. Clin Microbiol Rev 10 (1997) 35-66
4. Meyer K.F. Pneumonic plague. Bacteriol Rev 35 (1961) 249-261
5. Poland J.D., and Barnes A.M. Plague. In: Steel J.H. (Ed). CRC handbook series in Zoonoses. Section A. Bacterial, RickeT3Sial and mycotic diseases (1979), CRC Press, Boca Raton, FL, USA 515-597
6. WHO. Plague, democratic republic of the Congo. Wkly Epidemiol Rec 80 (2005) 86
7. Barnes A.M. Surveillance and control of bubonic plague in the United States. Symp Zool Soc London 50 (1982) 237-270
8. Cohen R.J., and Stockard J.L. Pneumonic plague in an untreated plague vaccinated individual. J Am Med Assoc 202 (1967) 365-366
9. Williamson E.D., Stagg A.J., Eley S.M., and Titball R.W. A sub-unit vaccine elicits IgG in serum, spleen cell cultures and bronchial washings and protects immunised animals against pneumonic plague. Vaccine 15 (1997) 1079-1084
10. Williamson E.D., Eley S.M., Griffin K.F., Green M., Russell P., Leary S.E.C., et al. A new improved sub-unit vaccine for plague: the basis of protection. FEMS Immun Med Micro 12 (1995) 223-230
11. Williamson E.D., Eley S.M., Stagg A.J., Green M., Russell P., and Titball R.W. A single dose sub-unit vaccine protects against pneumonic plague. Vaccine 19 (2001) 566-571
12. Anderson G.W., Leary S.E.C., Williamson E.D., Titball R.W., Welkos S.L., Worsham P.L., et al. Recombinant V antigen protects mice against pnuemonic and bubonic plague caused by F1- capsule-positive and -negative strains of Yersinia pestis. Infect Immun 64 (1996) 4580-4585
13. Andrews G.P., Heath D.G., Anderson Jr. G.W., Welkos S.L., and Friedlander A.M. Fraction 1 capsular antigen (F1) purification from Yersinia pestis CO92 and an Escherichia coli recombinant strain and efficacy against lethal plague challenge. Infect Immun 64 (1996) 2180-2187
14. Reisman R.E. Allergic reactions due to plague vaccine. J Allergy 46 (1970) 49-56
15. Bartelloni P.J., Marshall Jr. J.D., and Cavanaugh D.C. Clinical and serological responses to plague vaccine USP. Mil Med 138 (1973) 720-722
16. Marshall J.D., Bartelloni P.J., Cavanaugh D.C., Kadull P.J., and Meyer K.F. Plague immunisation. II. Relation of adverse clinical reactions to multiple immunisations with killed vaccine. J Infect Dis 129 (1974) S19-S25
17. Meyer K.F., Smith G., Foster L.E., Marshall J.D., and Cavanaugh D.C. Plague immunization. IV. Clinical reactions and serological responses to inoculations of Haffkine and freeze-dried plague vaccine. J Infect Dis 129 (1974) S30-S36
18. Speck R.S., and Wolochow H. Studies on the experimental epidemiology of respiratory infections. VIII. Experimental pneumonic plague in Macacus rhesus. J Infect Dis 100 (1957) 58-69
19. von Metz E., Eisler D.M., and Hottle G.A. Immunogenicity of plague vaccines in mice and guinea pigs. Appl Microbiol 22 (1971) 84-88
20. Powell B.S., Andrews G.P., Enama J.T., Jendrek S., Bolt C., Worsham P., et al. Design and testing for a non-tagged F1-V fusion protein as vaccine antigen against bubonic and pneumonic plague. Biotechnol Prog 21 (2005) 1490-1510
21. Williamson E.D. Plague vaccine research and development. J Appl Micro 91 (2001) 606-608
22. Williamson E.D., Flick-Smith H.C., Lebutt C.S., Rowland C.A., Jones S.M., Waters E.L., et al. Human immune response to a plague vaccine comprising recombinant F1 and rV antigens. Infect Immun 73 (2005) 3598-3608
23. Heath D.G., Anderson G.W., Mauro J.M., Welkos S.L., Andrews G.P., Adamovicz J., et al. Protection against experimental bubonic and pnuemonic plague by a recombinant capsular F1-V antigen fusion protein vaccine. Vaccine 16 (1998) 1131-1137
24. Anderson G.W., Heath D.G., Bolt C.R., Welkos S.L., and Friedlander A.M. Short- and long-term efficacy of single-dose subunit vaccines against Yersinia pestis in mice. Am J Trop Med Hyg 58 (1998) 793-799
25. Jones S.M., Day F., Stagg A.J., and Williamson E.D. Protection conferred by a fully-recombinant sub-unit vaccine against Yersinia pestis in male and female mice of four inbred strains. Vaccine 19 (2001) 358-366
26. Glyn A., Freytag L.C., and Clements J.D. Effect of homologous and heterologous prime-boost on the immune response to recombinant plague antigens. Vaccine 23 (2005) 1957-1965
27. Jones T., Adamovicz J.J., Cyr S.L., Bolt C.R., Bellerose N., Pitt L.M., et al. Intranasal Protollin™/F1-V vaccine elicits respiratory and serum antibody responses and protects mice against lethal aerosolized plague infection. Vaccine 24 (2006) 1625-1632
28. Jones S.M., Griffin K.F., Hodgson I., and Williamson E.D. Protective efficacy of a fully recombinant plague vaccine in the guinea pig. Vaccine 21 (2003) 3912-3918
29. Hill J., Leary S.E.C., Griffin K.F., Williamson E.D., and Titball R.W. Regions of Yersinia pestis V antigen that contribute to protection against plague identified by passive and active immunisation. Infect Immun 65 (1997) 4476-4482
30. Weeks S., Hill J., Friedlander A., and Welkos S. Anti-V antigen antibody protects macrophages from Yersinia pestis-induced cell death and promotes phagocytosis. Microb Pathogen 32 (2002) 227-237
31. Williamson ED, Stagg AJ, Eley SM, Taylor R, Green M, Jones SM, et al. Kinetics of the immune response to the (F1+V) vaccine in models of bubonic and pneumonic plague. Vaccine 2006;24, in press.
32. Pettersson J., Holmström A., Hill J., Leary S., Frithz-Lindsten E., von Euler-Matell A., et al. The V-antigen of Yersinia is surface exposed before cell contact and involved in virulence protein translocation. Mol Microbiol 32 (1999) 961-976
33. Mueller C.A., Broz P., Muller S.A., Ringler P., Erne-Brand F., Sorg I., et al. The V-antigen of Yersinia forms a distinct structure at the tip of injectisome needles. Science 310 (2005) 674-676
34. Cowan C., Philipovskiy A.V., Wulff-Strobel C.R., Ye Z., and Straley S.C. Anti-LcrV antibody inhibits delivery of Yops by Yersinia pestis KIM5 by directly promoting phagocytosis. Infect Immun 73 (2005) 6127-6137
35. Sing A., Rost D., Tvardovaskaia N., Roggenkamp A., Wiedemann A., Kirschning C., et al. Yersinia V-antigen exploits Toll-like receptor 2 and CD14 for interleukin 10-mediated immunosuppression. J Exp Med 196 (2002) 1017-1024
36. Overheim K.A., DePaolo R.W., DeBord K.L., Morrin E.M., Anderson D.M., Green N.M., et al. LcrV plague vaccine with altered immunomodulatory properties. Infect Immun 73 (2005) 5152-5159
37. Green M., Rogers D., Russell P., Stagg A.J., Bell D.L., Eley S.M., et al. The SCID/Beige mouse as a model to investigate protection against Yersinia pestis. FEMS Immunol Med Micro 23 (1999) 107-113
38. Hill J., Copse C., Leary S., Stagg A.J., Williamson E.D., and Titball R.W. Synergistic protection of mice against plague with monoclonal antibodies specific for the F1 and V antigens of Yersinia pestis. Infect Immun 71 (2003) 2234-2238
39. Carr S., Leary S.E.C., Miller J., Bennett A., Ho A., and Williamson E.D. Comparison of three different expression systems for production of the V antigen. Vaccine 18 (2000) 153-159
40. Williamson E.D., Vesey P.M., Gillhespy K.J., Eley S.M., Green M., and Titball R.W. An IgG1 titre to the F1 and V antigens correlates with protection against plague in the mouse model. Clin Exp Immun 116 (1999) 107-114
41. Russell P., Eley S.M., Hibbs S.E., Manchee R.J., Stagg A.J., and Titball R.W. A comparison of plague USP and EV76 Vaccine induced protection against Yersinia pestis in a murine model. Vaccine 13 (1995) 1551-1556